SecBot SecBot
SECBOTREPLAY Home › Report › PRCT

PRCT · PROCEPT BioRobotics disclosed its 2026 Analyst Day presentation,…

PROCEPT BioRobotics Corp · 8-K filed Feb 26, 2026 at 07:57 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 07:57 ET

PROCEPT BioRobotics disclosed its 2026 Analyst Day presentation, highlighting strong financial guidance with 2026 revenue projected between $390M and $410M (27-33% growth), improved gross margins targeting 65% in 2026 and 68-70% in 2027, and a clear path to profitability with adjusted EBITDA expected to turn positive in Q4 2026 and reach $25-30M gain in 2027. The company emphasized commercial execution, HYDROS system adoption, and expansion into prostate cancer treatment.

  • 2026 revenue guidance of $390M to $410M, representing 27% to 33% growth
  • 2027 revenue growth expected at 25% to 30%
  • 2026 gross margin guidance of 65%, targeting 68-70% in 2027
  • 2026 adjusted EBITDA loss guidance of $30M to $17M, with 2027 adjusted EBITDA gain of $25M to $30M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access